Adobe's Q2 2026 Earnings Update: Continued Deceleration

Adobe’s reported ARR included about $480 million from the Semrush acquisition, and organic ARR growth was 10.5% after adjusting for that deal. The article flags ten straight quarters of revenue growth deceleration, with opex growth of roughly 17% outpacing revenue growth of about 13% last quarter. Management kept FY'26 Total ARR growth guidance at 10.2% only by including the acquired Semrush ARR, which tempers confidence in the underlying trajectory.

Analysis

The important signal here is not the acquisition itself, but the fact that reported top-line stability is being masked by inorganic ARR while the core franchise keeps slowing. When a mature software platform is forced to lean on bought ARR to hit a growth target, the market usually starts to price in multiple compression because the narrative shifts from “durable compounding” to “managed optics.” That matters especially for a company that still trades partly on premium scarcity versus larger software peers.

The opex/revenue spread is the bigger medium-term issue because it implies operating leverage is no longer automatically accruing to equity holders. If expense growth stays above revenue growth for even a couple more quarters, incremental margin expansion gets delayed and every guide-up becomes less credible. In that regime, investors begin to question whether future deal activity is being used defensively to patch growth rather than offensively to accelerate it, which tends to lower the market’s willingness to underwrite more M&A.

Second-order, SEMR may benefit tactically from being embedded in a larger platform, but that does not necessarily translate into a clean rerating for the stock if the acquisition is perceived as ARR substitution rather than a strategic acceleration. The more likely knock-on is that other software buyers with slower organic growth will face heavier scrutiny on any future tuck-in acquisitions, and sell-side models will increasingly haircut “acquisition-assisted” growth versus true core demand. The setup is constructive for competitors that can still show organic mid-teens growth without relying on purchased revenue, because relative quality becomes the tradeable factor.

Contrarian risk: this can become a sentiment-driven short that gets crowded too early if management can show even modest reacceleration from product cycles or AI monetization over the next 1-2 quarters. But absent that, the burden of proof is shifting to upside surprises, not downside confirmation, and that usually keeps the stock capped until the market sees at least one clean quarter of organic re-acceleration and opex discipline.

Key Decisions for Investors

• Short ADBE on strength over the next 1-4 weeks; use rallies into results/guide revisions as entry points. Risk/reward favors downside if the market starts discounting acquisition-supported ARR and continued margin pressure.
• Pair trade: long higher-quality organic software names vs short ADBE for a 1-3 month horizon. The goal is to express relative quality as investors rotate toward names with cleaner core growth and better operating leverage.
• Avoid adding to ADBE until there is evidence of at least one quarter where organic ARR growth stabilizes and opex growth falls below revenue growth. This is a ‘show me’ story, not a momentum buy.
• For SEMR holders, treat any pop from deal-related sympathy as tactical only; trim into strength over days to weeks unless there is a separate fundamental rerating catalyst. The acquisition premium can evaporate if the market views the asset as a growth plug rather than a strategic unlock.
• Consider short-dated puts on ADBE around the next earnings cycle if implied volatility is not excessively rich. The catalyst path is asymmetric: another guide that depends on inorganic ARR can compress multiples faster than fundamentals improve.